Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles
Abstract
:1. Introduction
2. Results
2.1. Synthesis and Characterization of PLGA Nanoparticles
2.2. Oxyresveratrol Inhibited the Release of Pro-Inflammatory Cytokines by R848-Stimulated DCs
2.3. The Insertion of Oxyresveratrol in PLGA Nanoparticles Inhibited the Synergy between These Particles and R848 in Induction of Cytokine Release by DCs
2.4. Evaluation of Oxyresveratrol and PLGA Nanoparticle Toxicity on Human DCs
3. Discussion
4. Materials and Methods
4.1. Materials
4.2. Preparation of PLGA Nanoparticles
4.3. Size and ζ-Potential Characterization
4.4. Spectroscopic Studies, Encapsulation Efficiency and Release Evaluation
4.5. DC Preparation and Culture
4.6. Quantification of Cytokine Production
4.7. Cell Viability Evaluation
4.8. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Sample Availability
References
- Hilligan, K.L.; Ronchese, F. Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses. Cell. Mol. Immunol. 2020, 17, 587–599. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Xiang, Y.; Xin, V.W.; Wang, X.-W.; Peng, X.-C.; Liu, X.-Q.; Wang, D.; Li, N.; Cheng, J.-T.; Lyv, Y.-N.; et al. Dendritic cell biology and its role in tumor immunotherapy. J. Hematol. Oncol. 2020, 13, 1–18. [Google Scholar] [CrossRef] [PubMed]
- Anderson, D.A.; Dutertre, C.-A.; Ginhoux, F.; Murphy, K.M. Genetic models of human and mouse dendritic cell development and function. Nat. Rev. Immunol. 2021, 21, 101–115. [Google Scholar] [CrossRef]
- Vignali, D.A.A.; Kuchroo, V.K. IL-12 Family Cytokines: Immunological Playmakers. Nat. Immunol. 2012, 13, 722–728. [Google Scholar] [CrossRef] [Green Version]
- Floss, D.M.; Moll, J.M.; Scheller, J. IL-12 and IL-23—Close relatives with structural homologies but distinct immunological functions. Cells 2020, 9, 2184. [Google Scholar] [CrossRef]
- Zelová, H.; Hošek, J. TNF-α signalling and inflammation: Interactions between old acquaintances. Inflamm. Res. 2013, 62, 641–651. [Google Scholar] [CrossRef] [PubMed]
- Kaur, S.; Bansal, Y.; Kumar, R.; Bansal, G. A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. Bioorganic Med. Chem. 2020, 28, 115327. [Google Scholar] [CrossRef] [PubMed]
- Chow, T.G.; Gill, M.A. Regulation of allergic inflammation by dendritic cells. Curr. Opin. Allergy Clin. Immunol. 2020, 20, 56–63. [Google Scholar] [CrossRef] [PubMed]
- Saferding, V.; Blüml, S. Innate immunity as the trigger of systemic autoimmune diseases. J. Autoimmun. 2020, 110, 102382. [Google Scholar] [CrossRef] [PubMed]
- Švajger, U.; Obermajer, N.; Jeras, M. Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation: Resveratrol-induced dendritic cell tolerogenicity. Immunology 2010, 129, 525–535. [Google Scholar] [CrossRef] [PubMed]
- Panichakul, T.; Rodboon, T.; Suwannalert, P.; Tripetch, C.; Rungruang, R.; Boohuad, N.; Youdee, P. Additive effect of a combination of artocarpus lakoocha and glycyrrhiza glabra extracts on tyrosinase inhibition in melanoma B16 cells. Pharmaceuticals 2020, 13, 310. [Google Scholar] [CrossRef] [PubMed]
- Aziz, R.S.; Siddiqua, A.; Shahzad, M.; Shabbir, A.; Naseem, N. Oxyresveratrol ameliorates ethanol-induced gastric ulcer via downregulation of IL-6, TNF-α, NF-ĸB, and COX-2 levels, and upregulation of TFF-2 levels. Biomed. Pharmacother. 2019, 110, 554–560. [Google Scholar] [CrossRef] [PubMed]
- Ashraf, M.I.; Shahzad, M.K.; Shabbir, A. Oxyresveratrol ameliorates allergic airway inflammation via attenuation of IL-4, IL-5, and IL-13 expression levels. Cytokine 2015, 76, 375–381. [Google Scholar] [CrossRef] [PubMed]
- Wei, J.; Chen, J.-R.; Pais, E.M.A.; Wang, T.-Y.; Miao, L.; Li, L.; Li, L.-Y.; Qiu, F.; Hu, L.-M.; Gao, X.-M.; et al. Oxyresveratrol is a phytoestrogen exerting anti-inflammatory effects through NF-κB and estrogen receptor signaling. Inflammation 2017, 40, 1285–1296. [Google Scholar] [CrossRef] [PubMed]
- Hankittichai, P.; Lou, H.J.; Wikan, N.; Smith, D.R.; Potikanond, S.; Nimlamool, W. Oxyresveratrol inhibits IL-1β-induced inflammation via suppressing AKT and ERK1/2 activation in human microglia, HMC3. Int. J. Mol. Sci. 2020, 21, 6054. [Google Scholar] [CrossRef] [PubMed]
- Kumari, A.; Yadav, S.K.; Yadav, S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces 2010, 75, 1–18. [Google Scholar] [CrossRef] [PubMed]
- Fadeel, B. Hide and seek: Nanomaterial interactions with the immune system. Front. Immunol. 2019, 10, 133. [Google Scholar] [CrossRef] [PubMed]
- Najafi-Hajivar, S.; Zakeri-Milani, P.; Mohammadi, H.; Niazi, M.; Soleymani-Goloujeh, M.; Baradaran, B.; Valizadeh, H. Overview on experimental models of interactions between nanoparticles and the immune system. Biomed. Pharmacother. 2016, 83, 1365–1378. [Google Scholar] [CrossRef] [PubMed]
- Makadia, H.K.; Siegel, S.J. Poly lactic-co-glycolic acid (PLGA) As biodegradable controlled drug delivery carrier. Polymers 2011, 3, 1377–1397. [Google Scholar] [CrossRef] [PubMed]
- Danhier, F.; Ansorena, E.; Silva, J.M.; Coco, R.; Le Breton, A.; Préat, V. PLGA-based nanoparticles: An overview of biomedical applications. J. Control. Release 2012, 161, 505–522. [Google Scholar] [CrossRef]
- Lü, J.-M.; Wang, X.; Marin-Muller, C.; Wang, H.; Lin, P.H.; Yao, Q.; Chen, C. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn. 2009, 9, 325–341. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hespel, C.; Moser, M. Role of inflammatory dendritic cells in innate and adaptive immunity: Highlights. Eur. J. Immunol. 2012, 42, 2535–2543. [Google Scholar] [CrossRef] [PubMed]
- Jurk, M.; Heil, F.; Vollmer, J.; Schetter, C.; Krieg, A.M.; Wagner, H.; Lipford, G.B.; Bauer, S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 2002, 3, 499. [Google Scholar] [CrossRef] [PubMed]
- Frega, G.; Wu, Q.; Le Naour, J.; Vacchelli, E.; Galluzzi, L.; Kroemer, G.; Kepp, O. Trial Watch: Experimental TLR7/TLR8 agonists for oncological indications. OncoImmunology 2020, 9, 1796002. [Google Scholar] [CrossRef] [PubMed]
- Marongiu, L.; Donini, M.; Bovi, M.; Perduca, M.; Vivian, F.; Romeo, A.; Mariotto, S.; Monaco, H.L.; Dusi, S. The inclusion into PLGA nanoparticles enables α-bisabolol to efficiently inhibit the human dendritic cell pro-inflammatory activity. J. Nanoparticle Res. 2014, 16, 25541–25616. [Google Scholar] [CrossRef]
- Vogt, K.L.; Summers, C.; Chilvers, E.R.; Condliffe, A.M. Priming and de-priming of neutrophil responses in vitro and in vivo. Eur. J. Clin. Investig. 2018, 48, e12967. [Google Scholar] [CrossRef] [PubMed]
- Locati, M.; Curtale, G.; Mantovani, A. Diversity, mechanisms, and significance of macrophage plasticity. Annu. Rev. Pathol. Mech. Dis. 2020, 15, 123–147. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Harirforoosh, S.; Asghar, W.; Jamali, F. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J. Pharm. Pharm. Sci. 2013, 16, 821–847. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Whitehouse, M.W. Anti-inflammatory glucocorticoid drugs: Reflections after 60 years. Inflammopharmacology 2011, 19, 1–19. [Google Scholar] [CrossRef] [PubMed]
- Povichit, N.; Phrutivorapongkul, A.; Suttajit, M.; Chaiyasut, C.C.; Leelapornpisid, P. Phenolic content and in vitro inhibitory effects on oxidation and protein glycation of some Thai medicinal plants. Pak. J. Pharm. Sci. 2010, 23, 403–408. [Google Scholar]
- Hankittichai, P.; Buacheen, P.; Pitchakarn, P.; Na Takuathung, M.; Wikan, N.; Smith, D.R.; Potikanond, S.; Nimlamool, W. Artocarpus lakoocha extract inhibits LPS-induced inflammatory response in RAW 264.7 macrophage cells. Int. J. Mol. Sci. 2020, 21, 1355. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Radapong, S.; Sarker, S.D.; Ritchie, K.J. Oxyresveratrol possesses DNA damaging activity. Molecules 2020, 25, 2577. [Google Scholar] [CrossRef] [PubMed]
- Jia, Y.-N.; Lu, H.-P.; Peng, Y.-L.; Zhang, B.-S.; Gong, X.-B.; Su, J.; Zhou, Y.; Pan, M.-H.; Xu, L. Oxyresveratrol prevents lipopolysaccharide/d-galactosamine-induced acute liver injury in mice. Int. Immunopharmacol. 2018, 56, 105–112. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.S.; Kim, D.H.; Hong, J.E.; Lee, J.-Y.; Kim, E.J. Oxyresveratrol suppresses lipopolysaccharide-induced inflammatory responses in murine macrophages. Hum. Exp. Toxicol. 2015, 34, 808–818. [Google Scholar] [CrossRef]
- Teng, M.W.L.; Bowman, E.P.; McElwee, J.J.; Smyth, M.J.; Casanova, J.-L.; Cooper, A.M.; Cua, D.J. IL-12 and IL-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 2015, 21, 719–729. [Google Scholar] [CrossRef]
- Moschen, A.R.; Tilg, H.; Raine, T. IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 185–196. [Google Scholar] [CrossRef] [PubMed]
- Chyuan, I.-T.; Lai, J.-H. New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochem. Pharmacol. 2020, 175, 113928. [Google Scholar] [CrossRef] [PubMed]
- Steeland, S.; Libert, C.; Vandenbroucke, R.E. A new venue of TNF targeting. Int. J. Mol. Sci. 2018, 19, 1442. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fischer, R.; Kontermann, R.E.; Pfizenmaier, K. Selective targeting of TNF receptors as a novel therapeutic approach. Front. Cell Dev. Biol. 2020, 8, 401. [Google Scholar] [CrossRef] [PubMed]
- Waeckerle-Men, Y.; Scandella, E.; Allmen, E.U.-V.; Ludewig, B.; Gillessen, S.; Merkle, H.P.; Gander, B.; Groettrup, M. Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J. Immunol. Methods 2004, 287, 109–124. [Google Scholar] [CrossRef] [Green Version]
- Diwan, M.; Elamanchili, P.; Lane, H.; Gainer, A.; Samuel, J. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary t cell responses. J. Drug Target. 2003, 11, 495–507. [Google Scholar] [CrossRef] [PubMed]
- Lutsiak, M.E.C.; Robinson, D.R.; Coester, C.; Kwon, G.S.; Samuel, J. Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm. Res. 2002, 19, 1480–1487. [Google Scholar] [CrossRef] [PubMed]
- Dobrovolskaia, M.A.; Shurin, M.R.; Shvedova, A.A. Current understanding of interactions between nanoparticles and the immune system. Toxicol. Appl. Pharmacol. 2016, 299, 78–89. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Segat, D.; Tavano, R.; Donini, M.; Selvestrel, F.; Rio-Echevarria, I.; Rojnik, M.; Kocbek, P.; Kos, J.; Iratni, S.; Sheglmann, D.; et al. Proinflammatory effects of bare and PEGylated ORMOSIL-, PLGA- and SUV-NPs on monocytes and PMNs and their modulation by f-MLP. Nanomedicine 2011, 6, 1027–1046. [Google Scholar] [CrossRef] [PubMed]
- Chistè, E.; Ghafarinazari, A.; Donini, M.; Cremers, V.; Dendooven, J.; Detavernier, C.; Benati, N.; Scarpa, M.; Dusi, S.; Daldosso, N. TiO2-coated luminescent porous silicon micro-particles as a promising system for nanomedicine. J. Mater. Chem. B 2018, 6, 1815–1824. [Google Scholar] [CrossRef] [PubMed]
- Gaglio, S.C.; De Rosa, C.; Piccinelli, F.; Romeo, A.; Perduca, M. Complexes of rare earth ions embedded in poly(lactic-co-glycolic acid) (PLGA) nanoparticles: Characterization and spectroscopic study. Opt. Mater. 2019, 94, 249–256. [Google Scholar] [CrossRef]
Nanoformulation | Particles Size (nm) | Polydispersity Index | Ζ-Potential (mV) |
---|---|---|---|
EMPTY | 170.2 ± 2.5 | 0.049 ± 0.040 | −9.6 ± 0.4 |
PLGA(Oxy) | 169.6 ± 3.5 | 0.06 ± 0.02 | −7.1 ± 0.5 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gaglio, S.C.; Donini, M.; Denbaes, P.E.; Dusi, S.; Perduca, M. Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles. Molecules 2021, 26, 2106. https://doi.org/10.3390/molecules26082106
Gaglio SC, Donini M, Denbaes PE, Dusi S, Perduca M. Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles. Molecules. 2021; 26(8):2106. https://doi.org/10.3390/molecules26082106
Chicago/Turabian StyleGaglio, Salvatore Calogero, Marta Donini, Piyachat Evelyn Denbaes, Stefano Dusi, and Massimiliano Perduca. 2021. "Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles" Molecules 26, no. 8: 2106. https://doi.org/10.3390/molecules26082106